Biological treatment for erythrodermic psoriasis.
Dogra S, Mehta H.
Expert Opin Biol Ther. 2022 Dec;22(12):1531-1543. doi: 10.1080/14712598.2022.2128669. Epub 2022 Sep 28.
Psoriasis: a brief overview.
Raharja A, Mahil SK, Barker JN.
Clin Med (Lond). 2021 May;21(3):170-173. doi: 10.7861/clinmed.2021-0257.
[Erythrodermic psoriasis].
Rollin L, Rioual N, Aubret J, Dolghin M, Fouilland X.
Rev Prat. 2024 Jan;74(1):56-57.
Erythrodermic psoriasis improved by Tildrakizumab.
Trevisan G, Germi L, Naldi L.
Dermatol Reports. 2022 Nov 23;14(4):9448. doi: 10.4081/dr.2022.9448. eCollection 2022 Nov 21.
Treatment of erythrodermic psoriasis with biologics: A systematic review.
Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, Santiago-Vázquez M, Cancel-Artau KJ, Arias-Berrios G, Martín-García RF.
J Am Acad Dermatol. 2020 Jul;83(1):151-158. doi: 10.1016/j.jaad.2020.03.073. Epub 2020 Apr 2.
Erythrodermic psoriasis.
Mumoli N, Vitale J, Gambaccini L, Sabatini S, Brondi B, Cei M.
QJM. 2014 Apr;107(4):315. doi: 10.1093/qjmed/hct139. Epub 2013 Jun 12.
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S, Okubo Y, Tada Y, Ohtsuki M, Colston E, Napoli A, Shao Y, Banerjee S, Morita A.
J Dermatol. 2024 Mar;51(3):365-379. doi: 10.1111/1346-8138.17074. Epub 2024 Jan 24.
Erythrodermic Psoriasis Managed with Risankizumab.
Alajlan A, Madani A, Qadoumi TA, Aljaloud A, Alessa M.
Case Rep Dermatol. 2022 Aug 19;14(2):219-224. doi: 10.1159/000525774. eCollection 2022 May-Aug.
Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.
Shao S, Wang G, Maverakis E, Gudjonsson JE.
Drugs. 2020 Apr;80(6):525-534. doi: 10.1007/s40265-020-01283-2.
Psoriasis management tree based on comorbidity.
Amara S, Pasumarthi A, Parikh N, Kodali N, Lebwohl M, Monks G.
Int J Dermatol. 2025 Feb;64(2):229-245. doi: 10.1111/ijd.17497. Epub 2024 Oct 17.
